Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 8/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | GAK | O14976 | 1/20 | 0.40 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.40 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5120273 | 0.84 | MAPK14 (0.57) | MAPK14MAPK8MAPK1GAKRPS6KA4 | |
| SCHEMBL14038840 | 0.83 | MAPK14 (0.55) | MAPK14MAPK8MAPK1USP2ALDH1A1 | |
| SCHEMBL4173536 | 0.83 | MAPK14 (0.52) | MAPK14MAPK8MAPK1USP2ALDH1A1 | |
| SCHEMBL5113615 | 0.81 | BRD4 (0.44) | MAPK14MAPK8BRD4MAPK1USP2 | |
| SCHEMBL5110222 | 0.80 | MAPK14 (0.75) | MAPK14MAPK8 | |
| SCHEMBL29594724 | 0.80 | MAPK14 (0.75) | MAPK14MAPK8 | |
| SCHEMBL14014133 | 0.80 | MAPK14 (0.49) | MAPK14MAPK8MAPK1USP2ALDH1A1 | |
| SCHEMBL22126395 | 0.78 | MAPK14 (0.53) | MAPK14MAPK8BRD4MAPK1GAK | |
| SCHEMBL22126397 | 0.78 | MAPK14 (0.53) | MAPK14MAPK8BRD4MAPK1GAK | |
| SCHEMBL4186016 | 0.76 | MAPK14 (0.56) | MAPK14MAPK8MAPK1GAKRPS6KA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036472-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-05 | — | — | US | disclosed |
| US-7449581-B2 | 6-Substituted pyrido-pyrimidines | POCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449581-B2 | 6-Substituted pyrido-pyrimidines | POCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1846403-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | Ranbaxy Laboratories Limited (IN) | 2007-10-24 | — | — | EP | disclosed |
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | CHEN JIAN J | 2007-06-14 | — | — | US | disclosed |
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | CHEN JIAN J | 2007-06-14 | — | — | US | disclosed |
| US-7169794-B2 | 6-substituted pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169794-B2 | 6-substituted pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2007-01-30 | — | — | US | disclosed |
| WO-2006082492-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-10 | — | — | WO | disclosed |
| EP-1361880-B1 | 6-SUBSTITUTED PYRIDO-PYRIMIDINES | HOFFMANN LA ROCHE (CH) | 2005-09-28 | — | — | EP | disclosed |
| US-20040116698-A1 | 6-Substituted pyrido-pyrimidines | CHEN JIAN JEFFREY (US) | 2004-06-17 | — | — | US | disclosed |
| US-6696566-B2 | SELECTIVE P38 KINASE INHIBITORS RELATIVE TO CYCLIN-DEPENDENT KINASES AND TYROSINE KINASES | SYNTEX (U.S.A.) LLC | 2004-02-24 | — | — | US | disclosed |
| US-20030171584-A1 | Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. | SYNTEX (U.S.A.) LLC | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | P2RX6, P2RX1, P2RX7 | MAPK14 4250/4885MAPK8 3523/4885BRD4 261/4885 |
| US-20090036472-A1 | AZABICYCLO DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | IL1B, TPMT, IL1R1 | MAPK14 1323/4885MAPK8 2442/4885BRD4 1727/4885 |
| US-20030171584-A1 | Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. | ARRB1, MAPK1, MAPK8 | MAPK14 64/4885MAPK8 3/4885BRD4 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.